Asset Details
Do you wish to reserve the book?
Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease
Do you wish to request the book?
Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease
2013
Overview
Objective We wished to determine the effect of an acute coronary syndrome (ACS) on putative endothelial progenitor cell (EPC) populations, and define their relationship to coronary artery disease (CAD) severity and clinical outcome, in order to clarify their clinical relevance. Design and setting A prospective cohort study conducted in a tertiary referral cardiac centre. Patients Two-hundred-and-one patients undergoing coronary angiography for suspected angina or ACS. Main outcome measures Putative EPC populations were determined by flow cytometry. CAD was quantified using the Gensini scoring system. Survival free from revascularisation, recurrent myocardial infarction and death were determined at 3 years. Results Circulating CD34+VEGFR-2+ and CD34+VEGFR-2+CD133+ cells were rare (<0.007% of mononuclear cells), were not increased in patients with ACS, and were unrelated CAD severity or clinical outcome (p>0.1 for all). By contrast, CD34+CD45− cells were increased in patients with CAD compared with those with normal coronary arteries (p=0.008) and correlated with atheroma burden (r=0.44, p<0.001). Increased concentrations of circulating CD34+CD45− cells were associated with a shorter cumulative event-free survival (p<0.02). Proangiogenic monocytes (CD14+VEGFR-2+Tie-2+) and endothelial cell-colony forming units were increased in patients with ACS (p<0.01 for both), however, concentrations reflected myocardial necrosis, and did not predict the extent of CAD or clinical outcome. Conclusions Traditional EPC populations, CD34+VEGFR-2+ and CD34+VEGFR-2+CD133+ are not related to the extent of CAD or clinical outcome. However, CD34+CD45− cells are increased in patients with CAD and predict future cardiovascular events. It is likely that CD34+CD45− concentrations reflect the extent of vascular injury and atheroma burden.
Publisher
BMJ Publishing Group Ltd and British Cardiovascular Society,BMJ Publishing Group LTD
Subject
/ Coronary Artery Disease - diagnosis
/ Coronary Artery Disease - immunology
/ Coronary Artery Disease - therapy
/ Coronary Vessels - immunology
/ Coronary Vessels - pathology
/ Endothelium, Vascular - immunology
/ Endothelium, Vascular - metabolism
/ Endothelium, Vascular - pathology
/ Female
/ Humans
/ Leukocyte Common Antigens - immunology
/ Male
/ Myocardial Revascularization
/ Plaque, Atherosclerotic - diagnosis
/ Plaque, Atherosclerotic - immunology
/ Plaque, Atherosclerotic - therapy
/ Studies
/ Vascular Endothelial Growth Factor Receptor-2 - metabolism
